BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., and Hedley Technologies (USA) Inc., a wholly owned subsidiary, operates the Company’s business marketing biologically and health-friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn and Tibella, among others. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 is for the treatment of iron deficiency anemia. The firm also provides specialized healthcare products for dental hygiene and oral health.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Revenue
45
13
9
12
10
10
Revenue Growth (YoY)
18%
30%
13%
33%
25%
43%
Cost of Revenue
11
3
2
2
2
2
Gross Profit
34
10
7
9
7
8
Selling, General & Admin
21
6
4
5
5
5
Research & Development
0
0
0
0
0
0
Operating Expenses
22
6
5
5
5
5
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
12
3
2
3
2
3
Income Tax Expense
3
0
0
0
0
0
Net Income
9
2
1
2
2
2
Net Income Growth
28.99%
0%
0%
0%
100%
100%
Shares Outstanding (Diluted)
11.59
11.59
11.5
11.5
11.49
11.51
Shares Change (YoY)
1%
1%
-2%
-3%
-3%
-3%
EPS (Diluted)
0.78
0.2
0.17
0.23
0.17
0.2
EPS Growth
17%
0%
26%
19%
31%
35%
Free Cash Flow
12
2
3
2
3
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
75.55%
76.92%
77.77%
75%
70%
80%
Operating Margin
24.44%
23.07%
22.22%
25%
20%
20%
Profit Margin
20%
15.38%
11.11%
16.66%
20%
20%
Free Cash Flow Margin
26.66%
15.38%
33.33%
16.66%
30%
0%
EBITDA
12
3
2
3
2
2
EBITDA Margin
26.66%
23.07%
22.22%
25%
20%
20%
D&A For EBITDA
1
0
0
0
0
0
EBIT
11
3
2
3
2
2
EBIT Margin
24.44%
23.07%
22.22%
25%
20%
20%
Effective Tax Rate
25%
0%
0%
0%
0%
0%
Follow-Up Questions
What are BioSyent Inc.'s key financial statements?
According to the latest financial statement (Form-10K), BioSyent Inc. has a total asset of $0, Net loss of $0
What are the key financial ratios for BIOYF?
BioSyent Inc.'s Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is BioSyent Inc.'s revenue broken down by segment or geography?
BioSyent Inc. largest revenue segment is Pharmaceutical, at a revenue of 30,602,646 in the most earnings release.For geography, Canada is the primary market for BioSyent Inc., at a revenue of 30,300,745.
Is BioSyent Inc. profitable?
no, according to the latest financial statements, BioSyent Inc. has a net loss of $0